

Mengenal Penyakit Kardiovaskular & Solusinya untuk Dokter Umum



Bagian Kardiologi

Fakultas Kedokteran UnHas

RSUP Dr Wahidin Sudirohusodo Makassar

Muzakkir

Idar Mappangara

Akhtar M

Hakim Alkatiri

Yulius Patimang

Peter Kabo

MENGENAL PENYAKIT KARDIOVASKULAR & SOLUSINYA UNTUK DOKTER UMUM

Dr. dr. Muzakkir, Sp.JP
Dr. dr. Idar Mappangara, Sp.PD., Sp.JP
Dr. Akhtar M., Sp.JP
Dr. dr. Hakim Alkatiri, Sp.JP
Dr. Yulius Patimang, Sp.A, Sp.JP
Prof. dr. Peter Kabo, Ph.D., Sp.FK, Sp.JP



**UNIVERSITAS INDONESIA
PUBLISHING**

**MENGENAL PENYAKIT KARDIOVASKULAR & SOLUSINYA
UNTUK DOKTER UMUM**

Penulis: Prof. dr. Peter Kabo, Ph.D., Sp.FK, Sp.JP
Dr. dr. Muzakkir, Sp.JP
Dr. dr. Idar Mappangara, Sp.PD., Sp.JP
Dr. Akhtar M., Sp.JP
Dr. dr. Hakim Alkatiri, Sp.JP
Dr. Yulius Patimang, Sp.A, Sp.JP

xiv, 404 hlm.; 15 x 25 cm

ISBN: 978-623-333-024-4

e-ISBN: 978-623-333-022-0

©Hak Cipta Dilindungi Undang-Undang
Dilarang mengutip, memperbanyak dan menerjemahkan sebagian
atau seluruh isi buku ini tanpa izin tertulis dari penulis dan penerbit

Cetakan 2021

Diterbitkan pertama kali oleh UI Publishing
Anggota IKAPI & APPTI, Jakarta
Jalan Salemba 4, Jakarta 10430
Tel. +62 21 319-35373; 319-30172; 319-30252
Kompleks ILRC Gedung B Lt. 1 & 2
Perpustakaan Lama Universitas Indonesia
Kampus UI, Depok, Jawa Barat 16424
Tel. +62 21 788-88199; 788-88278
E-mail: uipublishing@ui.ac.id

DAFTAR ISI

DAFTAR ISI	iii
SAMBUTAN	ix
KATA PENGANTAR	xi

BAB I KONSEP DASAR

1. Jantung, Organ yang Luar Biasa	3
1. Sistem Konduksi	3
2. Otot Jantung	5
3. Vaskularisasi Koroner	7
2. Susunan Saraf Otonom dan Obat-Obat Otonom	13
1. Inervasi Susunan Saraf Otonom	13
2. Transmisi Susunan Saraf Otonom	15
3. Reseptor Susunan Saraf Otonom	17
4. Mekanisme Saraf Otonom Mengatur Fungsi Jantung	21
5. Reseptor Adrenergik pada Sistem Kardiovaskular & Mekanisme Signaling	21
6. Modulasi Neurotransmisi Otonom oleh Obat	25
7. Obat-Obat Otonom	28
3. Metabolisme Sel Miokardium	45
1. Metabolisme Sel Miokardium secara Fisiologi	46
2. Metabolisme Sel Miokardium pada Keadaan Iskemia	51
3. Gangguan Metabolisme Sel Miokard terhadap Kontraksi dan Relaksasi	53
4. Terapi Terkait Gangguan Metabolik pada Iskemia Miokard	55
4. Aterosklerosis dan Aterotrombosis	57
• Aterosklerosis	57
1. Fase Inisiasi Aterosklerosis	58
2. Aktivasi Endotel oleh Dislipidemia	59
3. Progresi Plak	64
4. Progresi Aterosklerosis & Presipitasi Sindrom Koroner Akut	65
• Aterotrombosis	66
1. Endotel	67
2. Trombosit	68
3. Sistem Koagulasi	69
4. Konsep Koagulasi Terkini	72
5. Progresi Aterotrombosis	75
6. Obat-Obat Hemostasis	76
5. Remote Ischemic Preconditioning (rIPC)	91

1.	Mekanisme Potensial dari rIPC	93
2.	Efek rIPC pada Darah dan Sistem Veaskular	97
3.	Aplikasi Klinik	98
6.	Terapi yang Rasional	99
1.	Evidence-Based Medicine (EBM)	99
2.	Faktor yang Memengaruhi Respons Tubuh terhadap Obat ..	104
3.	Mencapai Farmakoterapi yang Rasional	106

BAB II PEMERIKSAAN

1.	Elektrokardiografi (EKG)	109
1.	Lead atau Sandapan	109
2.	Elektrofisiologi Jantung	112
3.	Konfigurasi EKG	114
4.	Gambaran EKG Tidak Normal	119
5.	Membaca EKG secara Sistematis	126
2.	Treadmill test, Holter Monitoring & Cardiac Imaging.....	128
1.	Treadmill Test	128
2.	EKG Ambulatori.....	131
3.	Cardiac Imaging	134
3.	Ekokardiografi	142
1.	Jenis Pemeriksaan Ekokardiografi	142
2.	Nomenklatur	143
3.	Indikasi Pemeriksaan Ekokardiografi	147
4.	Parameter Pengukuran	147
4.	Angiografi Koroner & Angioplasti	151
1.	Indikasi Kateterisasi Jantung.....	152
2.	Risiko Angiografi Koroner	153
3.	Pengukuran Aliran Koroner.....	153
3.1	Studi Fisiologi Koroner	154
3.2	Studi Anatomi Koroner.....	155
4.	Angioplasti Koroner	157
5.	Pemeriksaan Fisik	159
1.	Inspeksi	159
2.	Palpasi	163
3.	Perkusi	165
4.	Auskultasi	166

BAB III HIPERTENSI

	171
1. Fisiologi & Patofisiologi	174
2. Patobiologi	177
3. Beberapa Pengertian Istilah yang Berhubungan dengan Hipertensi	179
4. Penemuan Klinis & Diagnosis	184
5. Blood Pressure Variability (BPV)	187
6. Tata laksana	187
6.1 Tata laksana Farmakologi	193
6.2 Kondisi Khusus	196
7. Obat-Obat Anti-Hipertensi	196
7.1 Diuretik	199
7.2 Anti-Adrenergik	202
7.3 Vasodilator	202
7.4 Calcium Channel Blockers	205
7.5 Penghambat RAAS	215
8. Krisis Hipertensi	216
8.1 Presentasi Klinis & Pemeriksaan Diagnostik	217
8.2 Klasifikasi	219
8.3 Etiologi & Patofisiologi	219
8.4 Presentasi Klinis pada Penyakit Khusus	219

BAB IV PENYAKIT JANTUNG KORONER

Faktor Risiko	225
Patobiologi Angina Pectoris	229
1. Sindrom Koroner Kronis (SKK).....	230
1.1 Gejala Klinik	230
1.2 Pemeriksaan Fisik	232
1.3 Pemeriksaan Dasar	232
1.4 Tata laksana	234
2. Sindrom Koroner Akut	248
Patofisiologi SKA	250
Pemeriksaan Fisik SKA.....	251
Pemeriksaan Non-Invasif & Invasif SKA	253
Diagnosis Banding	258
Tindakan Umum & Langkah Awal SKA	258
2.1 Sindrom Koroner Akut Non-Elevasi ST-Segmen.....	259
2.2 Infark Miokard Akut-Elevasi ST-Segmen	263

BAB V GAGAL JANTUNG

1.	Klasifikasi dan Prevalensi	273
2.	Etiologi	275
3.	Patogenesis Disfungsi Miokard	276
4.	Patofisiologi Gagal Jantung	279
5.	Tanda dan Gejala Klinis	281
6.	Algoritma Diagnosis Gagal Jantung	282
7.	Pemeriksaan dan Penilaian	285
8.	Tata laksana Gagal Jantung Kronis	287
9.	Diagnosis dan Tata laksana Gagal Jantung Akut	298

BAB VI ARITMIA

1.	Penyebab Aritmia	303
2.	Mekanisme Aritmogenik	304
3.	Penanggulangan	306
4.	Beberapa Aritmia yang Sering Dijumpai & Penanggulangan	312
4.1	Fibrilasi Atrium/Flutter Atrium	312
4.2	Takikardi Supraventrikular	312
4.3	Sindroma Wolff-Parkinson-White (WPW)	318
4.4	Sindrom Sinus Sakit (<i>Sick Sinus Syndrome</i> = SSS)	319
4.5	Ekstrasistol Ventrikel (<i>Ventricular Extrasystole</i> = VES)	319
4.6	Takikardi Ventrikel (<i>Ventricular Tachycardia</i> = VT) dan Fibrilasi Ventrikel (<i>Ventricular Fibrillation</i> = VF)	320
4.7	Blok	323
5.	Indikasi Pemasangan Pacu Jantung	330

BAB VII PENYAKIT ARTERI PERIFER

1.	Faktor Risiko	334
2.	Patofisiologi	335
3.	Diagnosis	336
3.1	Gambaran Klinis & Klasifikasi	336
3.2	Pemeriksaan Fisis	340
3.3	Tes Diagnostik	341
4.	Tata laksana	348

BAB VIII PENYAKIT JANTUNG BAWAAN (PJB)

1.	PJB asianotik	353
1.1	Lesi Pirau Kiri ke Kanan	355
1.1.1	Atrial Septal Defect (ASD)	355

1.1.2	Defek Septum Ventrikel	360
1.1.3	Duktus Arteriosus Persisten	364
1.2	Lesi Obstruksi Tanpa Pirau	367
1.2.1	Stenosis Pulmonal Kongenital	367
1.2.2	Stenosis Aorta Kongenital (AS)	369
2.	Penyakit Jantung Bawaan Sianotik	372
2.1	Lesi dengan Aliran Darah ke Paru Berkurang	372
2.1.1	<i>Tetralogy of Fallot</i> (TOF)	373
2.1.2	Pulmonary Atresia with Intact Ventricular Septum (PAIVS)	377
2.2	Lesi dengan Aliran Darah ke Paru Bertambah	378
2.2.1	<i>Transposition of the Great Arteries</i> (TGA)	379
2.2.2	<i>Double Outlet Right Ventricle</i> (DORV)	380
	Kepustakaan	383
	Indeks	397

BAB I. KONSEP DASAR

1. Jantung, Organ yang Luar Biasa

- Berry et al.** Importance of collateral circulation in coronary heart disease. *Eur Heart J.* 2007; 28: 278-291.
- Bers DM.** Cardiac excitation-contraction coupling. *Nature.* 2002; 415: 198-205.
- Fonseca DA et al.** The morphology, physiology dan pathophysiology of coronary microcirculation. *Disease biology – search/in Bio Discover.* 2016
- Katz AM.** *Physiology of the heart.* 3rd Ed. Philadelphia: Lippencott, Williams & Wilkins 2001.
- Liu X et al.** Native Coronary Collateral Microcirculation Reserve in Rat Hearts. *JAHA* 2019;8(5).
- Muller-Delp.** The Coronary Microcirculation in Health and Disease. *ISRN Physiology* 2013:238979; 1-24.
- Patel B et al.** Coronary Collateral Growth: Clinical Perspectives and Recent Insight. *IntechOpen* 2016. Doi 10.5772/67164.
- Park S-Y.** Cardiac, skeletal, and smooth muscle mitochondrial respiration. Are all mitochondria created equal? *Am L Physiol.* 2014; 307: H346-H352.
- Stoller M and Seiler C.** Pathophysiology of Coronary Collaterals. *Curr Cardiol Rev.* 2014;10 ;38-56.

2. Pengaruh Susunan Saraf Otonom pada Sistem Kardiovaskular

- Armour JS.** Cardiac neuronal hierarchy in health and disease. 2004; 287: R262-R267.
- Bowman WC & Rand MJ.** *Textbook of Pharmacology.* Chapter 9, 2nd ed. Blackwell Scientific Publication. 1984.
- Kabo P.** Modulation of noradrenergic transmission by endogenous mechanisms and by drugs acting at ion channels. PhD Thesis, Dept of Pharmacology, University of Melbourne, 1990.
- Kaniusas E et al.** Current Directions in the Auricular Vagus nerve stimulation I – A physiological perspective. *Front Neurosci.* 2019; 13: 854.
- Katzung BG.** Introduction to Autonomic Pharmacology. In: *Basic & Clinical pharmacology.* BG Katzung ed. 14 th Ed. Chapter 6. McGraw Hill Education. Lange. 2015.
- Lahlou S et al.** Cardiovascular effects of eugenol, a phenolic compound present in many plant essential oil, in normotensive rats. *J Cardiovasc Pharmacol.* 2004; 43: 250-257.
- Li H et al.** Curcumin, the Golden Spice in treating cardiovascular diseases. *Biotechnology Advances.* 2020; 38: 107343.

- Lymperopoulos A et al.** Adrenergic nervous system in heart failure. Pathophysiology & therapy. *Circ Res.* 2013; 113: 739-753.
- Olshansky B et al.** Parasympathetic nervous system & heart failure. Pathophysiology & potential implication for therapy. *Circulation.* 2008; 118: 863-871.
- Pharmacology Examination & Board review.** Anthony Trevor & B. Katzung. 2015
- Sarlak Z et al.** Interaction between the anti-oxidant activity of curcumin & cholinergic system on memory retention in adult male Wistar rats. *Iran J Basic Med Sci.* 2015; 18: 398-403.
- Westfall TC et al.** Adrenergic Agonists and Antagonists. Chapter 12. Goodman & Gilman's. *The Pharmacological Basic of Therapeutics.* Eds. 2018

3. Metabolisme Jantung

- Alexopoulos D et al.** Ranolazine reduces angina frequency & severity and improve quality of life. *Int J Cardiol.* 2016; 205:111-116.
- Badiger S.** Hyperglycaemia and Myocardial Infarction. *BJMP.* 2019; 12(2):a010.
- Brown DA et al.** Mitochondrial function as a therapeutic target in heart failure. *Nature reviews Cardiology.* 2017; 14: 238-250.
- Chakrabort S et al.** Oxidative Stress in Heart Diseases. Springer Nature Singapore Pte Ltd. 2019: 325-337.
- Dyck J & Lopaschuk G.** Malonyl CoA control of fatty acid oxidation in the ischemic heart. 2002; 34: 1099-1109.
- Gao Q et al.** Glycolysis and fatty acid β -oxidation, which one is the culprit of ischemic reperfusion injury?. *Int J Clin Exp Med.* 2018; 11(1):59-68.
- Guarini G et al.** Trimetazidine and Other Metabolic Modifiers. *European Cardiology Review.* 2018; 13(2):104-11.
- Jagdip S et al.** Optimizing cardiac energy substrate metabolism: a novel therapeutic intervention for ischemic heart disease. *Heart Metab.* 2008; 38: 5-14.
- Lopaschuk GD.** Metabolic Modulators in Heart Disease – Past, Present and Future, *Canadian Journal of Cardiology.* 2017; doi: 10.1016/j.cjca.2016.12.013.

4. Aterosklerosis dan Aterotrombosis

- Alfarisi HAH, et al.** Basic pathogenic mechanisms of atherosclerosis. *Egyptian Journal Of Basic And Applied Sciences.* 2020; 7: 116-125.

- Farag M et al.** Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. *Drug Des Dev Ther.* 2015; 9: 3801-07.
- Fox KA et al.** Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In: *Drugs for The Heart* 8th ed. Philadelphia: Elsevier Saunders. 2013: 332-356.
- Gambardella J et al.** Quit smoking to outsmart atherogenesis: molecular mechanisms underlying clinical evidence. *Atherosclerosis.* 2017; 257: 242-245.
- Hamidy MY.** Mekanisme Kerja dan Target Molekuler Interleukin-1 receptor antagonist (Anakinra) pada Aterosklerosis. *JIK, Jilid 11, 2017; Nomor 2, September; Hal. 59-64.*
- Hopkins PN.** Molecular Biology Of Atherosclerosis. *Physiol Rev.* 2013; 93: 1317–1542.
- Jackson AO, et al.** Molecular mechanisms and genetic regulation in atherosclerosis. *JC Heart & Vasculature.* 2018; 21: 36–44.
- Jing F & Zhang W.** Thrombosis Therapy: Focus on Antiplatelet Agents. *Int J Genomic Med.* 2013; 1: 1-6.
- Lee SW et al.** Cilostazol. In: *Antiplatelet Therapy in Cardiovascular Disease.* UK: Wiley Blackwell. 2014: 117-122.
- Lehman SJ et al.** Glycoprotein IIb/IIIa Inhibitors. In: *Platelets in Cardiovascular Disease.* London: Imperial College Press. 2008: 65-79.
- Li YR.** Anticoagulants, Platelet Inhibitors, and Thrombolytic Agents. In: *Cardiovascular Diseases: From Molecular Pharmacology to Evidence-Based Therapeutics.* USA: Wiley. 2015: 295-304.
- Marchio P et al.** Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. *Oxidative Medicine and Cellular Longevity J.* 2019; 19.
- Meiliana A et al.** Advanced in Molecular Mechanisms of Atherosclerosis. *Indones Biomed J.* 2018; 10: 104-22.
- Owens AP 3rd & Mackman N.** Tissue factor and thrombosis: The clot starts here. *Thromb Haemost.* 2010; 104: 432.
- Paneni F.** the ESC Textbook of vascular biology. *Eur Heart J.* 2017; 38. Doi:10.1093/eurheartj/ehx574.
- Palta S et al.** Overview of The Coagulation System. *Indian J Anaesth.* 2014; 58: 515-23.
- Park KH & Park WJ.** Endothelial dysfunction: clinical implication in cardiovascular disease and therapeutic approaches. *J Korean Med Science.* 2015; 30: 1213-1225.
- Patrono C et al.** Antiplatelet Agents for the Treatment and Prevention of

- Coronary Atherothrombosis. *J Am Coll Cardiol.* 2017;.70: 1760-64.
- Previtali E et al.** Risk factors for venous and arterial thrombosis. *Blood Transfus.* 2011; 9: 120-38
- Tian J et al.** Cellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach. *Oxidative Medicine and Cellular Longevity J.* 2017; Vol. 17.
- Versteeg HH et al.** New Fundamentals in Hemostasis. *Physiol Rev.* 2013; 93: 327-52.
- Wentzel JJ, et al.** The ESC Textbook of Vascular Biology : Chap. Biomechanical theories of atherosclerosis. Oxford Univ Press; ESC Working Group Atherosclerosis & Vascular Biology. 2017.
- Wallentin, Lars.** P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. *Eur Heart J.* 2009; 30: 1964-71.

5. Remote Ischemic Preconditioning (rIPC)

- Amstrong S et al.** Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic, stress & blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. *Cardiovasc Res.* 1994; 28: 72-77.
- Costa JF et al.** Myocardial remote ischemic preconditioning: from pathophysiology to clinical application. *Rev Port Cardiol.* 2013; 32: 893-904.
- Dow J et al.** The effect of acute versus delayed remote ischemic preconditioning on reperfusion induced ventricular arrhythmias. *J Cardiovasc Electrophysiol.* 2012. doi.org/10.1111/j.1540-8167.2012.02397.x
- Gassanov N et al.** Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? *Journal of the American Society of Nephrology.* 2014; 25: 216-24.
- Heusch G et al.** Remote ischemic conditioning. *Journal of the American College of Cardiology.* 2015; 65: 177-95.
- Jones H et al.** Seven-day remote ischemic preconditioning improves local & systemic endothelial function and microcirculation in healthy humans. *Am J Hypertens.* 2014; 27: 918-925.
- Lau JK et al.** Cardiac remote ischaemic preconditioning: mechanistic and clinical considerations. *Heart, Lung and Circulation.* 2017; 26: 545-53.
- Yang X-L et al.** Mechanism of cardioprotection by early ischemic preconditioning. *Cardiovasc Drug Ther.* 2010; 24: 225-234.

6. Rational Terapi

- Cleland JG.** Long term aspirin for coronary artery disease: are we being deceived by biased presentation of the evidence? *Future Cardiol.* 2010; 6: 141-146.
- Final report** on aspirin component of the ongoing physician' Health study. *N Engl J Med.* 1989; 321: 129-135.
- Guerrero-Garcia C & Rubio-Guerra AF.** Combination therapy in the treatment of hypertension. *Drugs Context.* 2018; 7: 212531.
- Jacobs D et al.** Report of the conference on low blood cholesterol: mortality association. *Circulation.* 1992; 86: 1046.
- Shivhare S et al.** Drug hazards & rational use of drugs : A review. *J Chem Pharm Res.* 2010; 2: 106-112.
- WHO.** Promoting rational use of medicine. Core components. September 2002. WHO. Geneva.

BAB II. PEMERIKSAAN

1. Elektrokardiografi (EKG)

- Brooks HL.** *Electrocardiography: 100 diagnostic criteria.* Chicago. Year Book Medical Publishers. 1991.
- Goldman MJ.** *Principles of Clinical Electrocardiography.* Tenth Ed, Lange Medical Publications, San Francisco, 1979.
- Marriott H.** *Practical Electrocardiography.* 8th ed, Baltimore, Williams & Wilkins, 1988.
- Mirvis DM & Goldberger AL:** *Electrocardiography. In Braunwald's Heart disease: a textbook of cardiovascular medicine (10th Ed).* Chapter 12. Eds. DL Mann, DP Zipes, P Libby & RO Bonow. (2015). Philadelphia: Elsevier Saunders.
- Shamroth L.** *The 12-lead Electrocardiogram.* London. Blackwell Scientific Publications, 1989.

2. Treadmill Test & Holter Monitoring

- Basalamah F et al.** *Pedoman Penggunaan Elektrokardiogram Ambulatori (EKGA).* PERKI. 2018
- Kharabsheh SM et al.** Overview of Exercise Stress Testing. *Ann Saudi Med.* 2006; 26(1):1-6
- Mubarik A & Iqbal AM.** *Holter Monitor.* NCBI Journal. 2020.
- Radi Basuni et al.** *Pedoman Uji Latih Jantung: Prosedur dan Interpretasi.* Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2016.

Ritchie JL et al. ACC/AHA Guidelines for Exercise Testing; A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. *Journal of American College of Cardiology*. 1997;260-315.

3. Ekokardiografi

Baysan O et al. Advances in echocardiography: global longitudinal strain, intra-cardiac multidirectional flow imaging and automated 3d volume analysis. *HVT J*. 2018; 2: 4.

Hwang IC et al. Association between global longitudinal strain and cardiovascular events in patients with LBBB assessed using two-dimensional speckle-tracking echocardiography. *J Am Soc Echocardiogr*. 2018; 31: 52-63.

Hillis, GS & Bloomfield P. Basic Transthoracic Echocardiography. *BMJ*. 2005; 330: 1432-36.

Mansi IA. 2020 'Echocardiography'. available from <https://emedicine.medscape.com/article/1820912-overview#a3>.

Mitchell C et al. 2018, Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*.

Mohamed AA et al. The Basics Of Echocardiography. *JSHA*. 2009; 22: 71-76.

Sicari R et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE)(a registered branch of the ESC). *Ejehocard*. 2008; 9: 415-37.

Zoghbi WA et al. Recommendations For Non Invasive Evaluation of Native Valvular Regurgitation. *J Am Soc Echocardiogr*. 2017; 30: 304-24.

4. Angiografi Koroner

Coronary Angiogram. mayoclinic. Oktober 2020, accessed from: <https://www.mayoclinic.org/tests-procedures/coronary-angiogram/about/pac-20384904>

Coronary CT Angiography. Neiman A, Ramjattan; Vasimahmed Lala; Omar Kousa; Amgad N, Makaryus. Stat Pearl. accessed from: <https://www.ncbi.nlm.nih.gov/books/NBK470279/>

Haryanto B. Percutaneous Coronary Intervention (PCI). pjhk.go.id. Oktober 2020, Oktober 2018, accessed from : <https://www.pjhk.go.id/artikel/percutaneous-coronary-intervention-pci>

- Intravascular Ultrasound (IVUS).** ptca.org. Oktober 2020. Februari 2013. accessed from <http://www.ptca.org/ivus/ivus.html>
- Ragosta M.** "Coronary And Peripheral Artery Hemodynamics," in *Text Book of Clinical Hemodynamics*, 2nd edition ed., vol. II, Philadelphia: Elsevier, 2018, pp. 270-292.
- Seike F et al.** "Intracoronary Optical Coherence Tomography- Derived Virtual Fractional Flow Reserve for the Assessment of Coronary Artery Disease." *Am J Cardiol.* 2017; 120: 1772-79.
- Tu S et al.** "Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: The International Multicenter FAVOR Pilot Study." *JACC Cardiovasc Interv.*, 2016; 9: 2024-35.
- Warisawa T.** "Past, Present and Future of Coronary Physiology" *Revista Española de Cardiología.* 2018; 71: 656-667

5. Imaging

- Braunwald's Heart disease:** a textbook of cardiovascular medicine (10th Ed). Chapter 16 (Nuclear Cardiology), Chapter 17 (Cardiovascular Magnetic Resonance Imaging), Chapter 18 (Cardiac computed tomography). (2015). Philadelphia: Elsevier Saunders.
- Hecht HS.** Coronary artery calcium scanning: Past, present, and future. *JACC Cardiovasc Imaging.* 2015;8(5):579-96.
- Klein R et al.** PET and SPECT Tracers for Myocardial Perfusion Imaging. *Semin Nucl Med [Internet].* 2020; 50(3): 208-18. Available from: <https://doi.org/10.1053/j.semnuclmed.2020.02.016>
- Ramjattan NA et al.** Coronary CT Angiography. [Updated 2020 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
- Sven P et al.** Cardiovascular MR Manual. *Journal of Chemical Information and Modeling.* London: Springer; 2011; 53: 428.

6. Pemeriksaan Fisis

- Ashley EA.** Cardiovascular examination – Cardiology explained – NCBI. 2004.
- Laukanen A et al.** practices of clinical examination of heart failure in primary care. *Cent Eur J Public Health.* 2006; 14: 86.
- Pemeriksaan Fisis Jantung.** Buku Acuan Peserta CSL-2. Fakultas Kedokteran, Universitas Hasanuddin. 2017.
- Silverman ME & Wooley CF.** Samuel A Levine & the history of grading

systolic murmurs. *Am J Cardiol.* 2008; 102: 1107-10.
Vukanovic-Criley JM et al. Competency in cardiac examination skills in medical student trainees, physicians, and faculty. A multicenter study. *Arch Intern Med.* 2006; 166: 610.

BAB. III. HIPERTENSI

- Benken ST.** Hypertensive emergencies. In: *CCSAP 2018. Book 1. Medical Issue In the ICU.* ACCP. 2018: 7-30.
- Benowitz NL.** Antihypertensive agents. *Basic & Clinical Pharmacology*, 14th ed, BG Katzung ed, Chapter 11, McGraw Hill Education. Lange. 2015.
- Born BH et al.** ESC Council on Hypertension Position Document on the Management of Hypertension Emergencies. *Eur Heart J.* 2018; 1-8.
- Hypertension: The silent killer: updated JNC-8. Guideline recommendation.**
- Kario K et al.** Morning surge in blood pressure as a predictor of silent & clinical cerebrovascular disease in elderly hypertensive. *Circulation.* 2003; 107: 1401-06.
- Kario K.** Morning surge in blood pressure & cardiovascular risk. Evidence & perspectives. *Hypertension.* 2010; 56; 765-73.
- O'Rourke M.** Mechanical Principles in Arterial Disease. *Hypertension.* 1995; 26: 2-9
- Parati G et al.** Assesment & management of blood-pressure variability. *Nature Review Cardiology.* 2013; 10: 143-55.
- Soenarta AA & Widiantoro B.** Hipertensi sistemik, mekanisme, diagnosis dan tata laksana. In: Y. Yuniadi, DY Hemanto, AU Rahajoe. Editors. *Buku ajar Kardiovaskular*, jilid 2. Jakarta. Sagung Seto, 2017; 62-89.
- Vaugan CJ & DelantyN.** Hypertensive emergencies. *Lancet.* 2000; 356: 411-17.
- Watson K et al.** Focused update on Pharmacologic Management of Hypertension Emergencies. *Curr Hypertens Rep.* 2018; 20: 1-8.
- William B et al.** 2018 ESC/ESH Guidelines ST. for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J [Internet].* 2018; 1-98.
- William B et al.** 2018 ESC/ESH guidelines for the management o arterial hypertension. *Eur Heart J.* 2018; 39: 1-98.

BAB IV. PENYAKIT JANTUNG KORONER

Kepustakaan

- Al-Attar N & Folliguet T.** The Heart Team to assess risk in coronary artery disease. An article from the e-journal of the ESC Council for Cardiology Practice. 2013; 11.
- Collet JP et al.** 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *European Heart Journal*. 2020; 00: 1-79. doi:10.1093/eurheartj/ehaa575.
- Ibanez B et al.** 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *European Heart Journal*. 2017; 00: 1-66. doi:10.1093/eurheartj/ehx393.
- Knuuti J et al.** 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). *European Heart Journal*. 2020; 41:407-77. doi:10.1093/eurheartj/ehz425.
- Lee MMY et al.** Statins in the prevention & treatment of heart failure: a review of evidence. *Curr Atheroscler Rep*. 2019; 21: 41
- Luo Z et al.** Effects of Astragalus injection & Salvia Miltiorrhiza injection on serum inflammatory markers in patients with stable coronary heart disease: a randomized controlled trial protocol. *BMC-trial* 21. 2020. Doi: 10.1186/s13063-020-4109-6.
- Ling H et al.** A Review of currently available fenofibrate and fenofibric acid formulations. *Cardiol Res*. 2013; 4: 47-55.
- Mach F et al.** 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *European Heart Journal*. 2020; 41: 111-88. doi:10.1093/eurheartj/ehz455.
- Maron DJ et al.** Initial invasive or conservative strategy for stable coronary disease. *N Eng J Med*. March 30, 2020. DOI:10.1056/NEJMoa1915922.
- Morrow DA & Lemos JA.** Stable Ischemic Heart Disease. In. Braunwald's Heart Disease, A Textbook Of Cardiovascular Medicine Eleventh Edition. Ed: Zipes, Libby, Bonow, Mann, Tomaselli. 2018: Elsevier.

- Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia.** Pedoman Tata laksana Sindrom Koroner Akut dengan ST-elevasi 2018.
- Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia.** Pedoman Tata laksana Sindrom Koroner Akut tanpa ST-elevasi 2004.
- Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia.** Panduan Evaluasi dan Tata laksana Angina Pektoris Stabil 2019.
- Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia.** Pedoman Tata laksana Panduan Pemilihan Modalitas Diagnostik Non Invasif pada Angina Pektoris Stabil 2020.
- Rosen A B & Gelfand E.** Pathophysiology of acute coronary syndromes. In. Management of Acute Coronary Syndromes. Eds: EV Gelfand and P Christopher. Cannon. 2009: John Wiley & Sons Ltd.
- Steven S et al.** The endothelin receptor antagonist Macitentan improves ISMN & ISDN induced endothelial dysfunction, oxidative stress, and vascular inflammation. Research article. <http://doi.org/10.1155/2018/7845629>.
- Thygesen K et al.** Fourth universal definition of myocardial infarction. European Heart Journal. 2018;00:1–33. doi:10.1093/eurheartj/ehy462.
- Valgimigli M et al.** 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2017;0:1–48. doi:10.1093/eurheartj/ehx419.
- Valgimigli M et al.** 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2018; 39, 213–254.

BAB V. GAGAL JANTUNG

- Albakri A.** Heart failure with reduced ejection fraction: A review of clinical status and meta-analyses of diagnosis by 3D echocardiography and natriuretic peptides-guided heart failure therapy. *Trends in Res*, 2018; 1(4): 1-2.
- Arrigo M et al.** Acute heart failure. Disease primer. 2020; 6:16
- Bistola V et al.** Inotropes in acute Heart Failure: from guidelines to practical use: therapeutic options & clinical practices. *Card Fail Rev*. 2019; 5: 133-39
- Duarte J & Cooper R.** Mechanism for blood pressure lowering and metabolics effect of thiazide and thiazide like diuretics. *Expert Rev Cardiovasc Ther*. 2010; 793-802

- Ferdinand KC & Mancini D.** Use of isosorbide dinitrate and hydralazine in African-American with heart failure, 9 years after African-American Heart Failure Trial. *Am J Cardiol.* 2014; 114: 151-59
- Forrester JS et al.** Correlation of clinical and hemodynamic function after acute myocardial infarction. *Am J Cardiol.* 1977; 39: 137-45.
- Januzzi JL & Mann DL.** Clinical assessment of heart failure. In *Braunwald's Heart disease: a textbook of cardiovascular medicine* (10th Ed). (2015). Philadelphia: Elsevier Saunders.
- Karabulut A et al.** The association between NT-proBNP level, functional capacity and stage in patients with heart failure. *Acta Cardiol.* 2005; 60: 631-38.
- Killip T & Kimball JT.** Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. *Am J Cardiol.* 1967; 20: 457-64.
- Koruth JS et al.** The Clinical Use of Ivabradine. *Journal of The American College of Cardiology.* 2017; 70 (14): 1777-84.
- McKelvie RS et al.** The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. *Can J Cardiol.* 2013; 29: 168-181.
- Moller MH et al.** Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. *Acta Anaesthesiologica Scandinavica.* 2018; 62: 420-50.
- Pardeep S J & McMurray JJV.** The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. *Heart* 2016; 102: 1342-47.
- Pashkovetsky E et al.** Use of Levosimendan in acute & advanced heart failure: short review on available real-world data. *Ther Clin Risk Manag.* 2019; 15: 765-72.
- Ponikowski P et al.** (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016; 37: 2129-2200.
- Samuel TJ et al.** Correcting calcium dysregulation in chronic heart failure using SERCA2a gene therapy. *Int J Mol Sci.* 2018; 19: 1086.
- Yancy CW et al.** (2013) ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* 2013; 62: e147-239.

BAB VI. ARITMIA

- DiMarco et al.** Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil. *Ann Intern Med.* 1990; 113: 104.
- Goldberger ZD & Shvilkin A.** (2018) 'Interpreting ECGs', in *Goldberger's Clinical Electrocardiography*. doi: 10.1016/b978-0-323-40169-2.00023-8.
- Goodman & Gilman's. The Pharmacological Basic of Therapeutics.** Eds: LL Brunton, JS Lazo & KL Parker. 7th ed. Chapter 34. McGraw-Hill Co. USA. 2006.
- Kashou AH & Kashou HE** (2018) Rhythm, Atrioventricular Block, StatPearls. Blackwell.
- Kabo P & Hanafiah A.** Atropin-resistant atrio-ventricular block in Non-Q-Wave myocardial infarction: The role of low dose aminophylline. *Med J Univ Indonesia.* 1994; 3:231.
- Kannel WB et al.** Epidemiologic features of chronic atrial fibrillation. *N Engl J Med.* 1982; 306: 1018.
- Kusumoto FM et al.** (2019) '2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm', *Journal of the American College of Cardiology*, 74(7), pp. e51–e156. doi: 10.1016/j.jacc.2018.10.044.
- Middlekauff MR et al.** Low-dose amiodarone for atrial fibrillation. *Am J Cardiol.* 1993; 72: 75F.
- Morady F and Scheinman MM.** Paroxysmal supraventricular tachycardia. Diagnosis and treatment. *Modern Concept of Cardiovascular Disease.* 1982; 51: 107.
- Olgin JE & Zipes DP.** Specific arrhythmias: Diagnosis & treatment. In: Braunwald's Heart Disease. A textbook of cardiovascular medicine. Eds: DL Mann, DP Zipes P Libby & RO Bonow, 10th Ed. Chapter 37. Saunders Elsevier, Philadelphia. 2015.
- Romulo F & Baltazar F** (2009) "*Basic and Bedside Electrocardiography*". Lippincott Williams & Wilkins
- Wipf JE and Lipsky BA.** Atrial fibrillation. Thromboembolic risk and indications for anticoagulation. *Arch Intern med.* 1990; 150: 1598.
- Yano M, Ikeda Y & Matsuzaki M.** Altered intracellular Ca⁺⁺ handling in heart failure. *J Clin Invest.* 2005; 115: 556-564.

BAB VII. PENYAKIT ARTERI PERIFER

- Abbaraogu UO et al.** Exercise therapy in routine management of peripheral arterial disease and intermittent claudication: a scoping review. *Ther Adv Cardiovasc Dis.* 2020; 14: 1–13
- Aboyans V et al.** 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Eur Heart J.* 2018; 39: 763–821
- AHA. ACCF/AHA Pocket Guideline November 2011:** Management of Patients With Peripheral Artery Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). American College of Cardiology Foundation, 2011.
- Akalu Y & Birhan A.** Peripheral Arterial Disease and Its Associated Factors among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia. *Journal of Diabetes Research,* 2020.
- Alahdab F et al.** A systematic review for the screening for peripheral arterial disease in asymptomatic patients. *J Vasc Surgery.* 2014; 61; 3S.
- Bevan GH & Solaru KT.** Evidence-Based Medical Management of Peripheral Artery Disease. *Arterioscler Thromb Vasc Biol.* 2020; 40:541–53.
- Campia U et al.** Peripheral Artery Disease: Past, Present, and Future. *The American Journal of Medicine.* 2019; 132: No 10.
- Firnhaber JM & Powell CS.** Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. *American Family Physician;* 2019;.99: No.6.
- Guirguis Blake JM et al.** Screening for Peripheral Artery Disease Using the Ankle-Brachial Index : Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* 2018; 320: 184-96.
- Hardman RL et al.** Overview of Classification Systems in Peripheral Artery Disease. *Semin Intervent Radiol.* 2014; 31: 378–88.
- Hinchliffe RJ et al.** IWGDF Guideline on diagnosis, prognosis and management of peripheral artery disease in patients with a foot ulcer and diabetes. IWGDF, 2019.
- McDermott MM & Criqui MH.** Ankle-Brachial Index Screening and Improving Peripheral Artery Disease Detection and Outcomes. *JAMA.* 2018; 320: 2.
- Mizzi A et al.** The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review. *Journal of Foot and Ankle Research.* 2019; 12: 40.
- Lau JF et al.** Peripheral artery disease. Part 1: clinical evaluation and non-

- invasive diagnosis. *Nat. Rev. Cardiol*, Macmillan Publisher May 2011.
- Olin JW et al.** Peripheral Artery: Disease Evolving Role of Exercise, Medical Therapy, and Endovascular Options. *Journal Of The American College of Cardiology*. 2016; 67: 11.
- Signorelli SS et al.** Pathophysiology of Peripheral Arterial Disease (PAD): A Review on Oxidative Disorders. *Int. J. Mol. Sci.* 2020; 21: 4393.

BAB VIII. PENYAKIT JANTUNG BAWAAN

- Kidd L et al.** Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. *Circulation*. 1993; 87(suppl): 138-51.
- Lilly Ls.** *Pathophysiology of heart disease*. Baltimore, Lippincott Williams Wilkins. 2007. pp 386-404.
- Odenwald T & Taylor AM.** Pulmonary valve interventions. *Expert Rev Cardiovasc Ther*. 2011; 9: 1445-57.
- Park M.** *Park's Pediatric Cardiology for practitioners*. Philadelphia, PA: Elsevier, Saunders. 2014.
- Rao P Syamasundar.** Diagnosis and management of acyanotic heart disease: Part I - Obstructive lesions. *Indian journal of pediatrics*. 2005; 72: 496-502. 10.1007/BF02724428.
- Rao P Syamasundar.** Diagnosis and management of acyanotic heart disease: Part II -left-to-right shunt lesions. *Indian journal of pediatrics*. 2005; 72: 503-12. 10.1007/BF02724429.
- Ten Harkel AD et al.** Congenital valvular aortic stenosis: limited progression during childhood. *Arch Dis Child*. 2009; 94: 531-5.
- Vijayalakshmi I.B.** *A comprehensive Approach to Congenital Heart Diseases*. New Delhi, Jaypee Publications. 2015.
- Warnes CA, Williams RG, Bashore TM, et al.** ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). *Circulation*. 2008; 118: 2395-451.
- Webb GD et al.** Congenital Heart Disease. In. Braunwald's heart disease: a textbook cardiovascular medicine. Chapter 62. 10th Edition. 2015. Philadelphia, Saunders.

Simarc-2, 85
 Sindroma Wolff-Parkinson-White (WPW),
 318
 Sindrom Cushing, 182, 219
 Sindrom HELLP, 195
 Sindrom Koroner Akut Non-Elevasi ST-
 Segmen (SKA-NEST), 249, 259
 SINDROM KORONER KRONIS, 230
 Sindrom Marfan, 162
 Sindrom X, 229
 Sinoatrial Exit Block, 323
 Sotalol, 37, 307, 309, 320
 Spell hipoksia, 372, 375, 376, 377
 Spironolakton, 193, 198, 246, 289, 290
 Splinter haemorrhage, 163
 Stator®, 245
 Streptokinase, 88, 89, 267
 ST-segmen depresi, 130
 ST-segmen elevasi, 124
 Sulfas kinidin, 307, 308
 Supra-ventricular tachycardia = SVT, 311

T

Takikardia atrium multifokal, 316
 Takikardia supraventrikular, 126, 311, 315,
 316
 Takikardia supraventrikular paroksismal,
 316
 Tanapress®, 212
 Telmisartan, 213, 215
 Tenecteplase, 89, 267
 Tenormin®, 42, 201
 Tensivask®, 204
 Terazosin, 36, 200
 Tetralogi of Fallot (TOF), 373
 Third Degree SA Block, 324
 Thrill, 163, 164, 169, 363, 368
 Ticagrelor, 76, 78, 79, 244, 259, 261, 262,
 267, 269, 270
 Tioxad®, 349
 Tirofiban, 76, 82, 83
 Tissue Plasminogen Activator (tPA), 76, 89
 Tonicard®, 293
 Torsade de Pointes, 322

Trandolapril, 212, 291
 Transposition of the Great Arteries (TGA),
 379
 Transthorakal Ekokardiografi (TTE), 142
 Traube sign (Pistol-shot sound), 164
 Trental®, 349
 Triatec®, 212
 Triflusal, 77
 Trigger Automatisasi, 304
 Trimetazidine, 53, 54, 55, 242, 243
 Trizedon MR®, 55, 242
 Trolip 160®, 246
 Tyarit®, 308

U

Unfractionated Heparin (UFH), 83
 Unstable Angina pectoris, 225, 228, 259
 UPERIO, 295

V

Vaclo®, 78
 Valsartan, 191, 213, 215, 291, 295
 Variant angina, 228
 Vasola®, 84
 Ventricle septal defect, VSD, 360
 Ventricular Extrasystole = VES, 319
 Ventricular Fibrillation = VF, 320
 Ventricular tachycardia = VT, 310
 Ventrikular ekstrasistol (VES), 119
 Verapamil, 173, 243, 297, 307, 309, 314,
 315, 316, 317, 326
 Vorapaxar, 76, 80, 244

W

Warfarin, 69, 85, 86, 87, 88, 104, 271, 314,
 349
 Wide fixed splitting, 168, 358

X

Xarelto®, 88

Z

Zanidip®, 204
 Zestril®, 212



**STRONG MINDS DISCUSS IDEAS.
AVERAGE MINDS DISCUSS EVENTS.
WEAK MINDS DISCUSS PEOPLE.**

Socrates (470-399 BC)



Muzakkir Amir : lahir di Makassar 10 Agustus 1971. Dokter Umum FK-UnHas (1997), Spesialis Jantung & Pemb. darah FK-UnAir (2007), Interventional Cardiology Chong-qing Med. Univ. China (2011), Elektrofisiologi & Device fellow, RS Harapan Kita-FKUI (2011), S3 FK-Unhas (2014). Jabatan sekarang: Ketua Dept. Kardiologi & Kedok. Vaskular. FK-UnHas (2017-).

Idar Mappangara : lahir di Makassar 21 Juli 1966. Dokter Umum FK-UnHas (1992), Spesialis Ilmu Penyakit Dalam FK-UnHas (2002), Spesialis Jantung & Pemb. darah FKUI (2007), S3 FK-UnHas (2013), Jabatan sekarang : KPS Ilmu Peny. Jantung & pemb. darah FK-UnHas (2014-). Ketua PERKI cabang Makassar.

Hakim Alkatiri : lahir di Manado 8 Juli 1968. Dokter Umum FK-UnSRat (1994), Spesialis Jantung & Pemb. darah FKUI (2005), S3 FK-UnHas (2017), Jabatan sekarang : SPS Ilmu Peny. Jantung & pemb. darah FK-UnHas.UnHas (2014-).

Akhtar Fajar Muzakkir : lahir di Makassar 25 Mei 1982. Dokter Umum FK-UnHas (2004), Spesialis Jantung & Pemb. darah FK-UnAir (2015), Jabatan sekarang : Sekretaris Dept. Kardiologi & Kedok. Vaskular. FK-UnHas (2017-).

Yulius Patimang : lahir di Bulungan 29 Juli 1967. Dokter Umum FK-UnHas (1995), Spesialis Ilmu Penyakit Anak FK-UnHas (2005), Kardiologi anak FKUI (2012), Spesialis Jantung & Pemb. darah FK-UnHas (2015).

Peter Kabo : lahir di Makassar 29 Maret 1950. Dokter Umum FK-UnHas (1976), PhD Dept. of Pharmacology, Melbourne Univ (1990), Spesialis Farmakologi Klinik FKUI (1995), Spesialis Jantung & Pemb. darah FKUI (1996), Guru Besar FK-UnHas (2002).

Komplek ILRC Gedung B Lt. 1 & 2
Perpustakaan Lama Universitas Indonesia,
Kampus UI, Depok, Jawa Barat - 16424
Tel. +62 21 7888 8199, 7888 8278

Jl. Salemba Raya No. 4, Jakarta Pusat - 10430
Tel. 319-35373, 319-30172, 319-30252
E-mail: uipublishing@ui.ac.id

